Hudson Value Partners’s ARK Genomic Revolution ETF ARKG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-14,605
Closed -$894K 113
2021
Q4
$894K Buy
14,605
+1,520
+12% +$105K 0.43% 64
2021
Q3
$978K Buy
13,085
+675
+5% +$56.6K 0.54% 62
2021
Q2
$1.15M Buy
+12,410
New +$1.06M 0.63% 52

Other funds holding ARKG

Hudson Value Partners's ARKG Position: Q1 2022 in Review

Hudson Value Partners sold out of ARK Genomic Revolution ETF (ARKG) in Q1 2022, closing a stake of 14,605 shares — an estimated $894K sold.

Hudson Value Partners first reported a position in ARKG in Q2 2021 and held it in 3 quarters. The position peaked at $1.15M in Q2 2021. 388 funds tracked by Wall St. Rank hold ARKG as of Q1 2022.

  • Hudson Value Partners reported no remaining ARK Genomic Revolution ETF position as of Q1 2022 after selling out during the quarter.
  • Hudson Value Partners sold 14,605 ARK Genomic Revolution ETF shares in Q1 2022, an estimated $894K.
  • Hudson Value Partners first reported a position in ARK Genomic Revolution ETF in Q2 2021 and held it in 3 quarters.
  • Hudson Value Partners's ARK Genomic Revolution ETF position peaked at $1.15M in Q2 2021.
  • 388 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q1 2022.

Based on Hudson Value Partners's 13F filing for Q1 2022, filed 14 Apr 2022.